Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.53), $0.10 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $34.17 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth